stockportfolio.pro
Supernus Pharmaceuticals, Inc. Total Debt 2010–2025
Supernus Pharmaceuticals, Inc. (SUPN) annual total debt (short- plus long-term borrowings) by fiscal year, computed from SEC filings.
| Fiscal year | Total Debt | Change (YoY) |
|---|---|---|
| FY 2025 | $0 | — |
| FY 2024 | $0 | — |
| FY 2023 | $0 | — |
| FY 2022 | $0 | -100.0% |
| FY 2021 | $379.25M | — |
| FY 2020 | $0 | — |
| FY 2019 | $0 | — |
| FY 2018 | $0 | — |
| FY 2017 | $0 | — |
| FY 2016 | $0 | — |
| FY 2015 | $0 | — |
| FY 2014 | $0 | — |
| FY 2013 | $0 | -100.0% |
| FY 2012 | $23.23M | — |
| FY 2011 | $0 | — |
| FY 2010 | $0 | — |
Source: Supernus Pharmaceuticals, Inc. SEC filings — balance sheet (10-K). Refreshed nightly.
See the full picture for Supernus Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSupernus Pharmaceuticals, Inc. — frequently asked questions
What is Supernus Pharmaceuticals, Inc.'s total debt (short- plus long-term borrowings)?
Supernus Pharmaceuticals, Inc. (SUPN) reported total debt (short- plus long-term borrowings) of $0 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (balance sheet (10-K)), refreshed nightly. Not investment advice.